Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2026

This “Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2026” report provides comprehensive insights about 140+ companies and 145+ pipeline drugs in Acute Lymphocytic Leukemia (ALL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also 2026 the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Lymphocytic Leukemia (ALL): Understanding

Acute Lymphocytic Leukemia (ALL): Overview

Acute lymphocytic leukemia (ALL) is also known as acute lymphoblastic leukemia which is a malignancy of B or T lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to the replacement of bone marrow elements and other lymphoid organs resulting in a typical disease pattern characteristic of acute lymphocytic leukemia.

Symptoms can include fatigue, easy or spontaneous bruising/bleeding, and infections. B-symptoms, such as fever, night sweats, and unintentional weight loss, are often present but may be mild. Hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central nervous system (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure.

Acute lymphocytic leukemia is thought to occur after damage to DNA causes lymphoid cells to undergo uncontrolled growth and spread throughout the body. Splenomegaly and hepatomegaly occur due to sequestration of platelets and lymphocytes in the spleen and liver; as the white blood cells are not typical, the spleen reacts to them by trying to remove them from the blood.

Acute Lymphocytic Leukemia diagnosis should be explored initially with a laboratory evaluation consisting of a CBC, electrolyte and renal panel, and LDH level. Additionally, imaging, such as a chest x-ray for symptoms of shortness of breath, may be obtained. If abdominal fullness, tenderness, or abdominal mass are symptoms, then a CT scan of the abdomen and pelvis should be obtained. This can also help with the staging of the disease.

Consolidation therapy is widely employed in current clinical practice and involves the use of various chemotherapeutic agents, yielding favorable outcomes. Maintenance therapy typically consists of oral 6-mercaptopurine or methotrexate administered on a weekly or monthly basis. The successful treatment of children with acute lymphocytic leukemia requires a multidrug regimen structured into distinct phases, including induction, consolidation, and maintenance, along with therapy targeting the central nervous system (CNS). More recently, CAR-T cell therapy has been explored in this setting and has demonstrated promising results, with several studies reporting high remission rates. However, CAR-T therapy is also associated with significant toxicities, such as cerebral edema and cytokine release syndrome, which may be fatal. Additionally, all blood products are required to be irradiated prior to transfusion to prevent transfusion-related graft-versus-host disease, a condition that is universally fatal.

"Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Lymphocytic Leukemia (ALL) pipeline landscape is provided which includes the disease overview and Acute Lymphocytic Leukemia (ALL) treatment guidelines. The assessment part of the report embraces, in depth Acute Lymphocytic Leukemia (ALL) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Lymphocytic Leukemia (ALL) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Lymphocytic Leukemia (ALL) R&D. The therapies under development are focused on novel approaches to treat/improve Acute Lymphocytic Leukemia (ALL).

Acute Lymphocytic Leukemia (ALL) Emerging Drugs Chapters

This segment of the Acute Lymphocytic Leukemia (ALL) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Lymphocytic Leukemia (ALL) Emerging Drugs

• Olverembatinib: Ascentage Pharma

Olverembatinib, a third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI), has demonstrated remarkable efficacy and a favorable safety profile in pts with CML resistant and/or intolerant to at least two TKIs or with T315I mutation. It works by binding to the ATP-binding site of the BCR-ABL1 tyrosine kinase, preventing phosphorylation, inhibiting signaling pathways, and inducing apoptosis in leukemic cells. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Acute Lymphocytic Leukemia.

• Orca-T: Orca Biosystems, Inc.

Orca-T is an investigational allogeneic T-cell immunotherapy under evaluation for the treatment of multiple hematologic malignancies including acute leukemias and myelodysplastic syndromes. Orca-T is composed of highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from either related or unrelated matched donors. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Acute Lymphocytic Leukemia.

• UCART22: Cellectis S.A.

UCART22(Lasme-cel) is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in BALLI-01. . It uses gene-edited, donor-derived T-cells targeting CD22, aimed at patients who have limited treatment options, including those who have relapsed after CD19-directed CAR-T therapies. In June 2024, the drug received Orphan drug designation, for the treatment of Acute Lymphoblastic Leukemia (ALL).According to the company, the drug is being evaluated in the Phase II stage of its development for the treatment of Acute Lymphocytic Leukemia.

• S1904 CD19 CAR-T: Hebei Senlang Biotechnology Inc., Ltd.

S1904 is a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy designed to treat relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Its mechanism of action (MOA) centers on using genetically engineered T-cells to identify and destroy CD19-positive (CD19+) malignant B-cells. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Acute Lymphocytic Leukemia.

• GT801: GRIT Biotechnology

GT801 is an investigational, systemically administered in vivo CAR-T product candidate that uses T-cell-targeted lipid nanoparticles (T-LNPs) to deliver optimized mRNA encoding an anti-CD19 CAR. The platform integrates Grit Bio's proprietary CLAMP (Controllable Ligand Attachment Modification and Purification) technology, enabling site-specific antibody conjugation, precise ligand density control, and selective T-cell targeting with minimal off-target uptake. GT801 is designed to generate potent and persistent CAR-T cells directly inside the patient, supporting repeat dosing and eliminating the need for conventional ex vivo cell manufacturing. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Acute Lymphocytic Leukemia.

• LV009: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

LV009 is an in vivo CAR-T/NK cell therapy designed to treat CD19-positive relapsed/refractory hematologic and lymphoid malignancies (such as non-Hodgkin lymphoma and acute lymphoblastic leukemia). Unlike traditional CAR-T therapy, which requires extracting, engineering, and expanding T-cells outside the body (ex vivo), LV009 is injected directly into the patient to generate CAR-T and CAR-NK cells within the body. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Acute Lymphocytic Leukemia.

Acute Lymphocytic Leukemia (ALL): Therapeutic Assessment

This segment of the report provides insights about the different Acute Lymphocytic Leukemia (ALL) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Lymphocytic Leukemia (ALL)

• There are approx. 140+ key companies which are developing the therapies for Acute Lymphocytic Leukemia (ALL). The companies which have their Acute Lymphocytic Leukemia (ALL) drug candidates in the most advanced stage, i.e. phase III include, Ascentage Pharma / Takeda.

Phases

The report covers around 145+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Lymphocytic Leukemia (ALL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Lymphocytic Leukemia (ALL): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Lymphocytic Leukemia (ALL) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Lymphocytic Leukemia (ALL) drugs.

Acute Lymphocytic Leukemia (ALL) Report Insights

• Acute Lymphocytic Leukemia (ALL) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Lymphocytic Leukemia (ALL) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Lymphocytic Leukemia (ALL) drugs?
• How many Acute Lymphocytic Leukemia (ALL) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Lymphocytic Leukemia (ALL)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Lymphocytic Leukemia (ALL) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Lymphocytic Leukemia (ALL) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ascentage Pharma
• Orca Biosystems, Inc.
• Wugen, Inc.
• Cellectis S.A.
• Hebei Senlang Biotechnology Inc., Ltd.
• Grit Biotechnology
• Nkarta, Inc.
• CytoCares Inc
• Shanghai Pharmaceuticals Holding
• OneChain Immunotherapeutics
• BIOHENG THERAPEUTICS US LLC
• Sumitomo Pharma America, Inc.
• AstraZeneca
• Excyte Biopharma Ltd
• Beam Therapeutics Inc.
• Shenzhen TargetRx Co., Ltd.
• Gyala Therapeutics
• TriArm Therapeutics (Taiwan) Limited
• Kymera Therapeutics, Inc.
• Wugen, Inc.
• Fate Therapeutics
• Meryx, Inc.
• PersonGen BioTherapeutics (Suzhou) Co., Ltd.
• Vincerx Pharma, Inc.
• FamiCordTx
• Tr1X, Inc.
• Nkarta, Inc.
• CytoCares Inc
• Shanghai Pharmaceuticals Holding
• OneChain Immunotherapeutics

Key Products

• Olverembatinib
• Orca-T
• WU-CART-007
• UCART22
• S1904 CD19 CAR-T
• GT801
• CTD402
• NKX019
• CC 312
• B-019
• CD1a-CAR T
• Enzomenib
• AZD0486
• YK 012
• BEAM-201
• TGRX 814
• GYA01
• ARM011
• WU-CART-007
• FT 819
• MRX 2843
• LV009
• VIP943
• FCTX-CL19-1
• TRX103

This product will be delivered within 2-4 business days.